nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2010 | Original Paper

High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma

verfasst von: Hyun Woo Chung, Eun Jeong Lee, Yo-Han Cho, So Young Yoon, Young So, Sung-Yong Kim, Mark Hong Lee, Jeong Hwan Kim, Sun-Young Lee, In-Kyung Sung, Hyung-Seok Park, Moon-Won Yoo, Kyung-Yung Lee

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated the role of FDG-PET/CT in patients with metastatic gastric adenocarcinoma before palliative chemotherapy to predict prognosis and chemotherapeutic response.

Methods

The study included 35 consecutive newly diagnosed patients with metastatic gastric adenocarcinoma who underwent FDG-PET/CT before palliative chemotherapy. Maximum standardized uptake value (SUVmax) of the primary tumor was assessed to evaluate survival and chemotherapeutic response. Survival analysis was performed for time to progression and overall survival using the Kaplan–Meier method. Cox proportional hazard models were used to determine independent prognostic factors.

Results

All primary tumors were visualized using FDG-PET/CT (mean SUVmax = 8.1 ± 4.5, range 2.5–22.1). Sensitivity, specificity, and accuracy of FDG-PET/CT in detection of solid organ metastasis were 95.2% (20/21), 100% (14/14), and 97.1% (34/35), respectively. No significant difference of primary tumor SUVmax was found among the chemotherapeutic response groups. Univariate survival analysis demonstrated ECOG performance status (≥2), presence of solid organ metastasis, number of organs involved in distant metastasis (≥2), and SUVmax of the primary tumor (>8) as significant predictors for poor overall survival. Multivariate survival analysis showed SUVmax of the primary tumor (P = 0.048), presence of solid organ metastasis (P = 0.015), and ECOG performance status (P = 0.002) as significant independent prognostic predictors for overall survival.

Conclusions

High FDG uptake of the primary tumor in patients with metastatic gastric adenocarcinoma is associated with poor overall survival. Assessment of tumor FDG uptake has limited value for prediction of chemotherapeutic response, but provides useful information regarding prognosis.

Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(2):ii31–ii36CrossRefPubMed

Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Shaha AR (2007) Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 14:3210–3215. doi:10.1245/s10434-007-9531-4 CrossRefPubMed

Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673. doi:10.1002/ijc.24290 CrossRefPubMed

Bomanji JB, Costa DC, Ell PJ (2001) Clinical role of positron emission tomography in oncology. Lancet Oncol 2:157–164CrossRefPubMed

Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 82:391–394. doi:10.1016/j.athoracsur.2006.03.045 discussion 394-5CrossRefPubMed

Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ et al (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103:2383–2390. doi:10.1002/cncr.21074 CrossRefPubMed

Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K (2009) FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 35:449–455. doi:10.1016/j.ejso.2008.11.010 PubMed

de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(1):43S–54S. doi:10.2967/jnumed.108.057224 CrossRefPubMed

Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C et al (2007) The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 10:221–227. doi:10.1007/s10120-007-0438-3 CrossRefPubMed

Dickson JL, Cunningham D (2004) Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 16:255–263CrossRefPubMed

Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S et al (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255–3260. doi:10.1200/JCO.2004.11.109 CrossRefPubMed

Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858–864. doi:10.2967/jnumed.108.057505 CrossRefPubMed

Han E, Choi W, Chung Y et al (2009) Comparison between FDG uptake and clinicopathologic and immunohistochemical parameters in pre-operative PET/CT scan of primary gastric carcinoma. Nucl Med Mol Imaging 43:26–34

Hicks RJ (2009) Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50(1):31S–42S. doi:10.2967/jnumed.108.057216 CrossRefPubMed

Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I et al (2005) 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 46:267–273PubMed

Hundahl SA, Menck HR, Mansour EG, Winchester DP (1997) The national cancer data base report on gastric carcinoma. Cancer 80:2333–2341CrossRefPubMed

Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY et al (2006) Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 33:148–155. doi:10.1007/s00259-005-1887-8 CrossRefPubMed

Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N et al (2003) FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 30:63–71. doi:10.1007/s00259-002-0978-z CrossRefPubMed

Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891. doi:10.1093/annonc/mdl501 CrossRefPubMed

Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K (2004) Evaluation of 18F–2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28:247–253. doi:10.1007/s00268-003-7191-5 CrossRefPubMed

Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K et al (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14:2012–2018. doi:10.1158/1078-0432.CCR-07-0934 CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed

Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF et al (2003) Results of the American college of surgeons oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1943–1951. doi:10.1016/j.jtcvs.2003.07.030 CrossRefPubMed

Rosati G, Ferrara D, Manzione L (2009) New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol 15:2689–2692CrossRefPubMed

Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288–295. doi:10.1007/s00259-002-1029-5 CrossRefPubMed

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M et al (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42:827–834. doi:10.1016/j.ejca.2005.08.044 CrossRefPubMed

van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ et al (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22:3805–3812. doi:10.1200/JCO.2004.01.083 CrossRefPubMed

Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T et al (2003) Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 44:690–699PubMed

Titel: High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma
verfasst von: Hyun Woo Chung
Eun Jeong Lee
Yo-Han Cho
So Young Yoon
Young So
Sung-Yong Kim
Mark Hong Lee
Jeong Hwan Kim
Sun-Young Lee
In-Kyung Sung
Hyung-Seok Park
Moon-Won Yoo
Kyung-Yung Lee
Publikationsdatum: 01.12.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0852-5

Springer Medizin

High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma